10025-MPC-3 DIFFERENCE AMONG GENERATIONS IN PATIENTS WITH HISTONE H3-MUTATED GLIOMAS

J. Fukai, Nobuhide Hayashi, H. Nakatogawa, Hiroshi Kawaji, Y. Kodama, T. Shofuda, E. Yoshioka, D. Kanematsu, A. Katsuma, Miho Sumida, Noriyuki Kijima, Y. Okita, K. Mori, Y. Kanemura
{"title":"10025-MPC-3 DIFFERENCE AMONG GENERATIONS IN PATIENTS WITH HISTONE H3-MUTATED GLIOMAS","authors":"J. Fukai, Nobuhide Hayashi, H. Nakatogawa, Hiroshi Kawaji, Y. Kodama, T. Shofuda, E. Yoshioka, D. Kanematsu, A. Katsuma, Miho Sumida, Noriyuki Kijima, Y. Okita, K. Mori, Y. Kanemura","doi":"10.1093/noajnl/vdad141.015","DOIUrl":null,"url":null,"abstract":"Abstract OBJECT This study investigates clinical and molecular features, including the survival outcomes, of patients with histone H3-mutant gliomas and the differences among generations: children (-13 years), adolescence and young adult (AYA) (14-39 years), and older adult (40- years) patients. Particularly, we focused on the older adult cases. METHODS We collected pediatric and adult glioma cases harboring histone H3 mutations (K27M and G34R/G34V) enrolled in Kansai Network (118 cases) and retrospectively analyzed clinical characteristics and genetic status, including overall survival times (OS). Additionally, the differences between the older adult (40- years) and the younger generations (-39 years) were evaluated. RESULTS The older adult patients were not infrequently enrolled in the H3 K27-mutant glioma group (n = 47) (40-79 years old)), although H3 G34-mutant glioma cases belonged to around AYA generation (11-45 years old). Most popular location was brainstem in children (8/15, 53%) and thalamus in AYA (29/56, 52%), while cerebrum as well as brainstem and thalamus were common in the older adults (15/47, 32%; 15/47, 32%; 11/47, 24%). Histologically, diagnosis of non-GBM was not uncommon (63/105, 60%). There were no significant age-specific differences in genetic status (IDH1/2, TERT promoter, MGMT promoter, TP53, BRAF, FGFR1, EGFR). In general, tumor biopsy followed by radiation and chemotherapy was the main treatment regimen regardless of patient age (92/115, 80%). Particularly in the H3 K27-mutant gliomas, there was no statistically significant difference in OS among generations (median OS of children/AYA/older adult, 16.6/18.4/15.9 months). CONCLUSIONS We report clinicopathological features and survival outcomes of histone H3-mutated glioma patients in Kansai Network cohort. Histone H3 mutation could exist in the older adult cases with diffuse gliomas at cerebral location. There was a little difference in clinical and pathological features among generations. The prognosis of the older adults was as poor as those of children and AYA.","PeriodicalId":19138,"journal":{"name":"Neuro-oncology Advances","volume":" 9","pages":"v4 - v4"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology Advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/noajnl/vdad141.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract OBJECT This study investigates clinical and molecular features, including the survival outcomes, of patients with histone H3-mutant gliomas and the differences among generations: children (-13 years), adolescence and young adult (AYA) (14-39 years), and older adult (40- years) patients. Particularly, we focused on the older adult cases. METHODS We collected pediatric and adult glioma cases harboring histone H3 mutations (K27M and G34R/G34V) enrolled in Kansai Network (118 cases) and retrospectively analyzed clinical characteristics and genetic status, including overall survival times (OS). Additionally, the differences between the older adult (40- years) and the younger generations (-39 years) were evaluated. RESULTS The older adult patients were not infrequently enrolled in the H3 K27-mutant glioma group (n = 47) (40-79 years old)), although H3 G34-mutant glioma cases belonged to around AYA generation (11-45 years old). Most popular location was brainstem in children (8/15, 53%) and thalamus in AYA (29/56, 52%), while cerebrum as well as brainstem and thalamus were common in the older adults (15/47, 32%; 15/47, 32%; 11/47, 24%). Histologically, diagnosis of non-GBM was not uncommon (63/105, 60%). There were no significant age-specific differences in genetic status (IDH1/2, TERT promoter, MGMT promoter, TP53, BRAF, FGFR1, EGFR). In general, tumor biopsy followed by radiation and chemotherapy was the main treatment regimen regardless of patient age (92/115, 80%). Particularly in the H3 K27-mutant gliomas, there was no statistically significant difference in OS among generations (median OS of children/AYA/older adult, 16.6/18.4/15.9 months). CONCLUSIONS We report clinicopathological features and survival outcomes of histone H3-mutated glioma patients in Kansai Network cohort. Histone H3 mutation could exist in the older adult cases with diffuse gliomas at cerebral location. There was a little difference in clinical and pathological features among generations. The prognosis of the older adults was as poor as those of children and AYA.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
组蛋白 h3 突变胶质瘤患者的 10025-mpc-3 代间差异
摘要目的本研究探讨组蛋白h3突变胶质瘤患者的临床和分子特征,包括生存结局,以及代际差异:儿童(-13岁)、青少年和青年(AYA)(14-39岁)和老年人(40岁)患者。我们特别关注老年人的病例。方法收集关西网络(Kansai Network)收录的儿童和成人组蛋白H3突变(K27M和G34R/G34V)胶质瘤病例(118例),回顾性分析临床特征和遗传状况,包括总生存时间(OS)。此外,还评估了老年人(40岁)和年轻一代(-39岁)之间的差异。结果:H3 k27突变型胶质瘤组的老年患者并不少见(n = 47)(40-79岁),尽管H3 g34突变型胶质瘤病例属于AYA代左右(11-45岁)。儿童最常见的部位是脑干(8/15,53%),AYA最常见的部位是丘脑(29/56,52%),老年人最常见的部位是大脑、脑干和丘脑(15/47,32%;15/47, 32%;11/47, 24%)。组织学上,非gbm的诊断并不罕见(63/ 105,60 %)。遗传状态(IDH1/2、TERT启动子、MGMT启动子、TP53、BRAF、FGFR1、EGFR)在年龄特异性上无显著差异。总体而言,无论患者年龄如何,肿瘤活检后放化疗是主要的治疗方案(92/115,80%)。特别是在H3 k27突变胶质瘤中,代际间的OS差异无统计学意义(儿童/AYA/老年人的中位OS为16.6/18.4/15.9个月)。结论:我们报告了关西网络队列中组蛋白h3突变胶质瘤患者的临床病理特征和生存结果。老年脑区弥漫性胶质瘤患者可能存在组蛋白H3突变。代际间临床及病理特征差异不大。老年人的预后与儿童和AYA一样差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Intensive pediatric chemotherapy regimen (PNET HR+5) in adult high-risk medulloblastoma and pinealoblastoma patients Longitudinal assessment of quality of life, neurocognition and psychopathology in patients with low-grade glioma on first-line temozolomide: a feasibility study Leveraging murine models of the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome to elucidate the cellular circuits that drive pediatric low-grade glioma formation and progression FGFR1 gene mutation as a potential risk factor for spontaneous intracranial hemorrhage in pediatric low grade glioma patients Medulloblastomas with ELP1 pathogenic variants: a weakly penetrant syndrome with a restricted spectrum in a limited age window
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1